Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy

Journal of Nuclear Medicine

Volumn 44, Issue 11, 2003, Pages 1806-1814

  Mankoff, David A ^a,b   Dunnwald, Lisa K ^a   Gralow, Julie R ^a   Ellis, Georgiana K ^a   Schubert, Erin K ^a   Tseng, Jeffrey ^a   Lawton, Thomas J ^a   Linden, Hannah M ^a   Livingston, Robert B ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Division of Nuclear Medicine   (United States)

Author keywords

15O water; 18F FDG; Breast cancer; Neoadjuvant chemotherapy; PET; Response

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT;

ADJUVANT CHEMOTHERAPY; ARTICLE; BLOOD FLOW; BREAST CARCINOMA; CANCER SURVIVAL; GLUCOSE METABOLISM; HUMAN; METABOLIC RATE; METABOLISM; MOLECULAR BIOLOGY; MOLECULAR DYNAMICS; PRIORITY JOURNAL; ADULT; AGED; BREAST TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE FREE SURVIVAL; FEMALE; MIDDLE AGED; VASCULARIZATION;

ADULT; AGED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; REGIONAL BLOOD FLOW; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0642376397     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Beahrs OH. Staging of cancer. CA Cancer J Clin. 1991;41:21-125.
2. Hortobagyi GN. Comprehensive management of locally advanced breast cancer. Cancer. 1990;66:1387-1391.
3. Feldman LD, Hortobagyi GN, Buzdar AU, Ames FC, Blumenschein GR. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res. 1986;46:2578-2581.
4. Machiavelli MR, Romero AO, Perez JE, et al. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma. Cancer J Sci Am 1998;4:125-131.
5. Pinder SE, Wencyk P, Sibbering DM, et al Assessment of the new proliferation marker MIBI in breast carcinoma using image analysis, associations with other prognostic factors and survival. Br J Cancer. 1995;71:146-149.
6. Pertschuk LP, Feldman JG, Kim YD, et al. Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Sp gamma in frozen sections or cytosol-based ligand-binding assays. Cancer. 1996;77:2514-2519.
7. Thor AD, Moore DH, Edgerton SM, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers J Natl Cancer Inst 1992;84:845-855.
8. Mankoff DA, Dunnwald LK, Gralow JR, et al. Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med 2002;43:500-509.
9. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol. 1993;11:2101-2111.
10. Bassa P, Kim EE, Inoue T, et al. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med 1996;37:931-938.
11. Jansson T, Westlin JE, Ahlstrom H, Lilja A, Langstrom B, Bergh J. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol. 1995;13:1470-1477.
12. 18F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000;18:1676-1688.
13. 18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol. 2000;18:1689-1695
14. Placido SD, Carlomagno C, Ciardiello F, et al Measurement of neovascularization is an independent prognosticator of survival in node-negative breast cancer patients with long-term follow-up. Clin Cancer Res. 1999;5:2854-2559.
15. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8.
16. Hortobagyi GN, Ames FC, Buzdar AU, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer. 1988;62:2507-2516.
17. Mankoff DA, Dunnwald LK, Gralow JR, Ellis GK, Drucker MJ, Livingston RB. Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibt scintimammography. Cancer. 1999;85:2410-2423.
18. Hayward JL, Carbone PP, Heuson J-C, Kumaoka S, Segaloff A, Reubens RD Assessment of response to therapy in advanced breast cancer. Cancer. 1977;39:1289-1294.
19. Lewellen TK, Kohlmyer S, Miyaoka R, Schubert S, Stearns C. Investigation of the count rate performance of the General Electric ADVANCE positron emission tomograph. IEEE Trans Nucl Sci. 1995;42:1051-1057.
20. 18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med. 1986;27:235-238.
21. Weinberg IN, Huang SC, Hoffman EJ, et al. Validation of PET-acquired input functions for cardiac studies. J Nucl Med 1988;29:241-247.
22. Wilson CB, Lammertsma AA, McKenzie CG, Sikora K, Jones T Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and non-invasive dynamic method. Cancer Res. 1992;52:1592-1597.
23. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab. 1983;3:1-7.
24. Kohlmyer S, Vesselle H, Miyaoka R, Kaplan M, Lewellen T. Comparison of recovery coefficients for PET based on maximum and average ROI pixel values. Abstract presented at European Association of Nuclear Medicine Annual Meeting; 2000: Paris, France. Abstract OS.329.
25. McCready DR, Hortobagyi GN, Kau SW, Smith TL, Buzdar AU, Balch CM. The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. Arch Surg. 1989;124:21-25.
26. Jain RK. Haemodynamic and transport barriers to the treatment of solid tumors. Int J Radiat Biol 1991;60:85-100.
27. Scopinaro F, Schillaci O, Scarpini M, et al Technetium-99m sestamibi: an indicator of breast cancer invasiveness Eur J Nucl Med. 1994;21:984-987.
28. Abraham DC, Jones RC, Jones SE, et al Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging. Cancer. 1996;78:91-100.
29. Gilles R, Guinebretiere JM, Toussaint C, et al. Locally advanced breast cancer: contrast-enhanced subtraction MR imaging of response to preoperative chemotherapy. Radiology 1994;191:633-638
30. Kedar RP, Cosgrove DO, Smith IE, Mansi JL, Bamber JC. Breast carcinoma: measurement of tumor response to primary medical therapy with color flow Doppler imaging. Radiology 1994;190:825-830.
31. Maini CL, Tofani A, Sciuto R, et al. Technetium-99m-MIBI scintigraphy in the assessment of neoadjuvant chemotherapy in breast carcinoma J Nucl Med. 1997;38:1546-1550.
32. Esserman L, Kaplan E, Partridge S, et al. MRI phenotype is associated with response to doxombicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer Ann Surg Oncol. 2001;8:549-559
33. Sutherland RM. Tumor hypoxia and gene expression. Acta Oncol. 1998;37:567-574.
34. Teicher BA. Hypoxia and drug resistance Cancer Metastasis Rev. 1994;13:139-168
35. Green SL, Amato AJ. Tumor hypoxia and the cell cycle: implications for malignant progression and response to therapy. Cancer J Sci Am. 1998;4:218-223.
36. Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem. 1994;269:23757-23763.
37. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-induced angiogenesis. Nature. 1992;359:843-845
38. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 1996;379:88-91.
39. Brand K. Aerobic glycolysis by proliferating cells: protection against oxidative stress at the expense of energy yield. J Bioenerg Biomembr. 1997;29:355-364.
40. Mathupala SP, Rempel A, Pedersen PL. Aberrant glycolytic metabolism of cancer cells: a remarkable coordination of genetic, transcriptional, post-translational, and mutational events that lead to a critical role for type II hexokinase J Bioenerg Biomembr. 1997;29:339-343.